Anastasis Biotec

Executive Summary

Anastasis Biotec is a UK-based biotechnology company founded in 2021, focused on developing a novel cancer treatment that leverages patient tumor biopsies to identify critical mutations and match them with appropriate pathway inhibitors. The company's proprietary technology aims to control cancer and cancer stem cell proliferation by targeting specific driver mutations. Currently in Phase 1/2 clinical development, Anastasis Biotec has not disclosed total funding or valuation. Its approach represents a precision medicine strategy that could improve outcomes for patients with actionable mutations. The company operates in the competitive oncology landscape but differentiates itself through its mutation-driven inhibitor matching. Given its early stage, success hinges on demonstrating safety and efficacy in ongoing trials.

Upcoming Catalysts (preview)

• Q3 2026Release of Phase 1/2 interim data40% success
• Q4 2026Announcement of strategic partnership or licensing deal30% success